HIV Oral Drug Composition Patent

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.

View original document View source feed page

What changed

The USPTO granted Patent US12594244B2 to Gilead Sciences for a therapeutic composition comprising tenofovir alafenamide, emtricitabine, and a compound of Formula I in a solid oral dosage form. The patent names inventors Benjamin Micah Collman, Lei Hong, and Joanna M. Koziara. This grant provides Gilead with exclusive rights to this specific HIV treatment formulation in the United States.

Pharmaceutical companies developing generic HIV treatments or similar fixed-dose combinations should review this patent for freedom-to-operate considerations. Competitors seeking to develop alternative oral HIV therapies should ensure their formulations do not infringe the 29 claims. No immediate compliance deadline applies as this is a patent grant rather than a regulatory requirement.

Source document (simplified)

← USPTO Patent Grants

Therapeutic compositions for treatment of human immunodeficiency virus

Grant US12594244B2 Kind: B2 Apr 07, 2026

Assignee

Gilead Sciences, Inc.

Inventors

Benjamin Micah Collman, Lei Hong, Joanna M. Koziara

Abstract

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

CPC Classifications

A61K 9/209 A61K 9/0053 A61K 9/2013 A61K 9/2027 A61K 9/2054 A61K 9/2086 A61K 9/2095 A61K 9/28 A61K 9/2833 A61K 31/513 A61K 31/5365 A61K 31/537 A61K 31/553 A61K 31/675 A61P 31/18